Cotellic
Publisher: Datamonitor Healthcare
- Description
- Companies
- Contents
- Enquire
Drug Overview
Cotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. Cotellic specifically binds to and inhibits the catalytic activity of MEK, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation. In preclinical studies, oral dosing of Cotellic resulted in potent and sustained inhibition of MEK in RAS or BRAF mutant tumor models.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Cotellic : Melanoma
20 Cotellic : Colorectal cancer (CRC)
LIST OF FIGURES
12 Figure 1: Cotellic in melanoma – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Cotellic for melanoma
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Cotellic for melanoma
16 Figure 4: Cotellic sales for melanoma across the US and five major EU markets, by country, 2017–26
25 Figure 5: Cotellic for colorectal cancer – SWOT analysis
26 Figure 6: Datamonitor Healthcare’s drug assessment summary of Cotellic for colorectal cancer
27 Figure 7: Datamonitor Healthcare’s drug assessment summary of Cotellic for colorectal cancer
29 Figure 8: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Cotellic drug profile
7 Table 2: Cotellic pivotal trial data in melanoma
9 Table 3: Cotellic early-phase data in melanoma
11 Table 4: Cotellic ongoing late-phase trials in melanoma
17 Table 5: Cotellic sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
19 Table 6: Cotellic patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
20 Table 7: Cotellic drug profile
22 Table 8: Cotellic Phase III trial in colorectal cancer
24 Table 9: Cotellic early-phase data in colorectal cancer
30 Table 10: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
32 Table 11: Patients treated with Cotellic in the US and five major EU markets, by country, 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch 
Sign up to the